Warfarin therapy
91 results
1 - 91
Don't add aspirin to warfarin therapy except with mechanical heart valve- Discontinuing warfarin therapy indefinitely after GI bleeding assoc with worse outcomes
- Continued warfarin better than bridging therapy for pacemaker or defibrillator surgery (BRUISE CONTROL)
- Warfarin superior to antiplatelet treatment for A Fib
- Warfarin can safely be held for the short term
- Benefits to resuming warfarin in patients with atrial fibrillation after intracranial bleeds
- Tinzaparin no better than warfarin in preventing recurrent VTE in adults with cancer
- Continuing warfarin for 18 months after unprovoked PE reduces risk of recurrent VTE
- Warfarin: damned if you do, damned if you don't
- Bleeding risk with warfarin high among elderly, especially older than 80
- Many patients using warfarin also take aspirin
- Clinically significant bleeding occurs in 3.8% per year of pts aged 65+ years using warfarin
- 6 months of warfarin after aortic valve replacement reduces risk of CV death
- Dual therapy with dabigatran and clopidogrel preferred after PCI for patients with AF (RE-DUAL PCI)
- Closure of PFO similar to medical therapy for cryptogenic stroke or TIA
- More harm than good with bridge therapy in low-risk VTE patients
- NOACs preferred over warfarin for nonvalvular atrial fibrillation in patients also taking low-dose aspirin
- Dabigatran reduces risk of stroke and embolism in patients with AF
- Percutaneous left atrial appendage closure reduces AF stroke risk
- Rivaroxaban + clopidogrel causes somewhat less bleeding than triple therapy in patients with AF undergoing PCI
- Coumadin + aspirin no better than aspirin alone for PAD
- Extended anticoagulation may be helpul for patients with unprovoked VTE or PE
- Genetic information does not add benefit to a clinical algorithm for warfarin management
- ACC/AHA guidelines for atrial fibrillation
- Genotype-guided perioperative warfarin dosing may not be superior to algorithm-guided dosing
- Use of antithrombotic medications increases risk of hematuria-related complications
- Taking vitamin K antagonists after ICH: the good, the bad, and the ugly (CHIRONE)
- Clopidogrel + ASA for afib: fewer strokes, more hemorrhages (ACTIVE)
- Joint injection okay in anticoagulated patients
- Rivaroxaban similar to warfarin for patients with NVAF
- Dabigatran cost-effective for AF prophylaxis in some patients, not others
- VTE recurrence higher in men
- Slightly lower risk of major bleeds with apixaban (NNT = 83); no difference in efficacy
- Oral rivaroxaban as effective as standard therapy for treatment of acute PE
- Rivaroxaban effective for acute DVT (EINSTEIN)
- Dabigatran associated with increased risk of coronary events
- Bridging anticoagulation in patients with AF associated with more CVEs and bleeding
- Anticoagulation reversal with vitamin K doesn't reduce bleeding
- ACCP 2016: updated guidelines for VTE
- Updated American College of Chest Physicians guideline on antithrombotic therapy for venous thromboembolism
- 2023 American Geriatric Society update on potentially inappropriate medication use in the elderly (Beers List)
- ACCP guidelines for antithrombotics in atrial fibrillation
- Aspirin is no different than other anticoagulants for VTE prevention after joint replacement surgery
- For atrial fibrillation with ACS or PCI, apixaban plus clopidogrel (without aspirin) is preferred (AUGUSTUS)
- D-dimer can identify high-risk group for extended anticoagulation (PROLONG)
- The DOAC score determines bleeding risk for patients with atrial fibrillation who take a direct-acting oral anticoagulant